Research Analysts Issue Forecasts for ACAD Q1 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for shares of ACADIA Pharmaceuticals in a research report issued on Thursday, November 6th. HC Wainwright analyst A. Fein anticipates that the biopharmaceutical company will earn $0.12 per share for the quarter. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q2 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.24 EPS, FY2027 earnings at $2.54 EPS, FY2028 earnings at $2.74 EPS and FY2029 earnings at $2.89 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.14 by $0.28. ACADIA Pharmaceuticals had a return on equity of 14.69% and a net margin of 21.80%.The business had revenue of $278.63 million for the quarter, compared to the consensus estimate of $276.52 million. During the same quarter in the prior year, the business earned $0.20 earnings per share. ACADIA Pharmaceuticals’s revenue for the quarter was up 11.3% on a year-over-year basis. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS.

Several other research analysts also recently weighed in on ACAD. Weiss Ratings reiterated a “hold (c)” rating on shares of ACADIA Pharmaceuticals in a research note on Tuesday, October 14th. TD Cowen increased their target price on shares of ACADIA Pharmaceuticals from $35.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, September 11th. Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. The Goldman Sachs Group boosted their price target on shares of ACADIA Pharmaceuticals from $15.00 to $17.00 and gave the company a “sell” rating in a research report on Thursday, August 7th. Finally, Citigroup initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, October 21st. They set a “buy” rating and a $33.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $28.94.

ACADIA Pharmaceuticals Price Performance

Shares of ACAD opened at $22.57 on Friday. The firm has a market cap of $3.81 billion, a PE ratio of 16.97, a PEG ratio of 7.90 and a beta of 0.80. The stock’s fifty day moving average price is $22.62 and its two-hundred day moving average price is $21.95. ACADIA Pharmaceuticals has a 1 year low of $13.40 and a 1 year high of $26.65.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ACAD. Geneos Wealth Management Inc. lifted its position in ACADIA Pharmaceuticals by 113.0% during the third quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 756 shares during the last quarter. Banque Transatlantique SA bought a new position in shares of ACADIA Pharmaceuticals in the 1st quarter worth $31,000. Picton Mahoney Asset Management purchased a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter valued at $32,000. Smartleaf Asset Management LLC raised its position in shares of ACADIA Pharmaceuticals by 107.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 885 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of ACADIA Pharmaceuticals by 231.5% during the 1st quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,618 shares during the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Insider Buying and Selling at ACADIA Pharmaceuticals

In related news, Director Elizabeth A. Garofalo sold 1,600 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $25.98, for a total transaction of $41,568.00. Following the completion of the transaction, the director directly owned 25,382 shares in the company, valued at $659,424.36. The trade was a 5.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark C. Schneyer sold 22,000 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $25.18, for a total value of $553,960.00. Following the completion of the transaction, the executive vice president owned 40,130 shares in the company, valued at $1,010,473.40. This represents a 35.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 27,098 shares of company stock worth $678,256. Insiders own 26.50% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.